Shepherin II Gene Synthesis and Peptide Characterization: E. coli Expression, Purification, and Antiviral Activity

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Elfattah A.A.; Samir S.; Okasha H.; Atef A.A.; Taha A.

Journal: Protein and Peptide Letters

Publisher: Bentham Science Publishers

Publication Date: October 2026

Volume / Issue: Volume 32 / Issue 10

Pages: 756–768

ISSN: 9298665

DOI: 10.2174/0109298665413796251002111415

Scopus: View on Scopus

PubMed: 41140082

Document Type: Article


Authors and Affiliations

Elfattah A.A., Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt; Samir S., Department of Biochemistry and Molecular Biology, Theodor Bilharz Research Institute, Giza, 12411, Egypt; Okasha H., Department of Biochemistry and Molecular Biology, Theodor Bilharz Research Institute, Giza, 12411, Egypt; Atef A.A., Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt; Taha A., Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt


Abstract

Introduction: The shepherin II peptide is characterized by a histidine/glycine-rich sequence. This study aimed to design, express recombinantly, and evaluate the antiviral activity of shepherin II against hepatitis A virus (HAV). Methods: The shepherin II gene was reverse-translated, cloned into the pET-3a vector, and expressed in E. coli BL21 (DE3) pLysS cells induced with 2 mM IPTG. Purification was achieved via cation exchange chromatography, and intact mass analysis using mass spectrometry was carried out. Cytotoxicity on normal Vero cells and antiviral activity on HAV were evaluated. Results: The mass spectrometry confirmed a primary peptide fragment with a molecular weight of 3,421.30 Da (100% relative abundance). SDS-PAGE verified peptide expression. Cytotoxicity tests on Vero cells showed a CC50 of 219.26 ± 7.91 µg/ml. Antiviral assay revealed an EC50 of 113.92 ± 4.58 µg/ml against HAV, resulting in a selectivity index (SI) of 1.92. This SI indicates limited selectivity compared to the reference drug amantadine, which exhibited an EC50 of 5.67 ± 0.71 µg/ml and an SI of 53.41. Discussion: The recombinant expression of shepherin II was successfully achieved and confirmed by mass spectrometry and SDS-PAGE. The peptide showed measurable antiviral activity against HAV. Conclusion: This study demonstrated the feasibility of recombinant shepherin II production and assessed its antiviral activity. However, the limited selectivity index of shepherin II remains a challenge that needs to be addressed through molecular modification or alternative delivery strategies to improve its clinical potential. 2025, Bentham Science Publishers


Keywords

antimicrobial peptide; antiviral activity; HAV; Histidine-glycine rich peptide; recombinant DNA technology; shepherin peptides; Animals; Antiviral Agents; Chlorocebus aethiops; Escherichia coli; Gene Expression; Hepatitis A virus; Peptides; Recombinant Proteins; Vero Cells; amantadine; antivirus agent; isopropyl thiogalactoside; shepherin II peptide; unclassified drug; peptide; recombinant protein; Article; bacterial gene; BL21 gene; CC50 (cytotoxic concentration); controlled study; cytotoxicity; cytotoxicity test; drug design; drug purification; drug synthesis; EC50; gene synthesis; ion exchange chromatography; mass spectrometry; molecular weight; nonhuman; peptide analysis; polyacrylamide gel electrophoresis; selectivity index; Vero cell line; animal; biosynthesis; chemistry; drug effect; genetics; isolation and purification; metabolism


Citation Information

Scopus Citations: 1


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region

Corrigendum to ‘Eco-friendly approach for the removal and simultaneous detection of cyanide toxins from drinking and wastewater sources’ [Environ. Pollut. 385 (2025) 127094]